Cardiff Oncology (NASDAQ:CRDF) PT Lowered to $7.00

Cardiff Oncology (NASDAQ:CRDFGet Rating) had its target price lowered by Piper Sandler from $20.00 to $7.00 in a research note issued on Friday, The Fly reports. Piper Sandler’s target price would indicate a potential upside of 442.64% from the stock’s current price.

Other research analysts have also issued research reports about the stock. Robert W. Baird dropped their price target on shares of Cardiff Oncology from $13.00 to $9.00 in a research note on Tuesday, May 10th. HC Wainwright dropped their price target on shares of Cardiff Oncology from $25.00 to $22.00 in a research note on Monday, May 9th. Finally, Zacks Investment Research upgraded shares of Cardiff Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Cardiff Oncology has an average rating of “Buy” and a consensus target price of $11.80.

Shares of CRDF traded up $0.09 during mid-day trading on Friday, hitting $1.29. 15,410 shares of the company’s stock were exchanged, compared to its average volume of 770,008. The firm has a fifty day moving average of $1.79 and a two-hundred day moving average of $3.61. Cardiff Oncology has a twelve month low of $1.13 and a twelve month high of $8.58. The stock has a market cap of $55.86 million, a price-to-earnings ratio of -1.57 and a beta of 2.04.

Cardiff Oncology (NASDAQ:CRDFGet Rating) last announced its quarterly earnings results on Friday, May 6th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Cardiff Oncology had a negative return on equity of 25.12% and a negative net margin of 9,447.37%. As a group, equities research analysts forecast that Cardiff Oncology will post -1.05 EPS for the current year.

Institutional investors have recently modified their holdings of the business. Citigroup Inc. boosted its holdings in Cardiff Oncology by 105.1% in the 4th quarter. Citigroup Inc. now owns 10,574 shares of the company’s stock valued at $64,000 after purchasing an additional 5,419 shares during the period. Metropolitan Life Insurance Co NY acquired a new position in shares of Cardiff Oncology in the 3rd quarter valued at $74,000. Quantbot Technologies LP acquired a new position in shares of Cardiff Oncology in the 1st quarter valued at $28,000. Invesco Ltd. acquired a new position in shares of Cardiff Oncology in the 2nd quarter valued at $87,000. Finally, HighVista Strategies LLC acquired a new position in shares of Cardiff Oncology in the 3rd quarter valued at $103,000. 56.43% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile (Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Further Reading

The Fly logo

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.